Pre-made Carotuximab benchmark antibody ( Whole mAb, anti-ENG therapeutic antibody, Anti-END/HHT1/ORW1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-095

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-095 Category Tag

Product Details

Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.

Products Name (INN Index)

Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody

INN Name

Carotuximab

Target

ENG

Format

Whole mAb

Derivation

Chimeric (Mouse/Human)

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2015

Companies

National Cancer Institute (USA),Santen Pharmaceutical,TRACON Pharmaceuticals,University of Alabama at Birmingham,University of Minnesota,Roswell Park Cancer Institute

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Fallopian tube cancer,Ovarian cancer,Peritoneal cancer,Prostate cancer,Haemangiosarcoma,Choriocarcinoma,Glioblastoma,Liver cancer,Renal cell carcinoma,Soft tissue sarcoma,Breast cancer,Non-small cell

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

ENG

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide